检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

In-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in multiple myeloma (MM) by age and frailty status: updated subgroup analysis from the fully accrued US MM-6 study

Saulius Girnius,Joshua Richter,Roger Lyons,Kimberly Bogard,Sudhir Manda,Ruemu Birhiray,Habte Yimer,Kim Tran,Suman Kambhampati,Jyoti Arora,Stephen Noga,Robert Rifkin

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）

引用 0|浏览4
暂无评分
关键词
parenteral bortezomib,multiple myeloma,oral ixazomib,frailty status,in-class
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要